Legal & General Group PLC Tyme Technologies, Inc. Transaction History

Legal & General Group PLC

  • $440 Billion
  • Q2 2024

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 12, 2021
SELL
$1.14 - $1.87 $7,976 - $13,084
-6,997 Closed
0 $0
Q1 2021

May 17, 2021
SELL
$1.34 - $3.53 $3,065 - $8,076
-2,288 Reduced 24.64%
6,997 $12,000
Q1 2020

May 14, 2020
SELL
$0.9 - $1.95 $2,798 - $6,062
-3,109 Reduced 25.08%
9,285 $10,000
Q4 2019

Feb 13, 2020
BUY
$1.0 - $1.49 $2,315 - $3,449
2,315 Added 22.97%
12,394 $17,000
Q3 2019

Nov 13, 2019
SELL
$0.97 - $1.77 $5,866 - $10,704
-6,048 Reduced 37.5%
10,079 $12,000
Q4 2018

Feb 15, 2019
BUY
$2.01 - $4.21 $19,804 - $41,481
9,853 Added 157.04%
16,127 $60,000
Q2 2018

Aug 10, 2018
BUY
$2.05 - $4.09 $12,861 - $25,660
6,274 New
6,274 $20,000

About TYME TECHNOLOGIES, INC.

TYME Quotes by TradingView
  • Ticker TYME
  • Exchange NASDAQ
  • Shares Outstandng 172,207,008
  • Description
  • Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...
More about TYME
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email